|
|
Navigating the Rapidly Evolving Classification and Treatment Landscape of Secondary AML Subtypes: Modeling Best Practices for Early Identification and Individualized Care
Are you optimally treating secondary AML subtypes per latest evidence on selection of therapies? To optimize treatment, clinicians must not only have current knowledge of the up-to-date classification and risk stratification strategies, but the operational frameworks to effectively translate this latest evidence into treatment selection practices. Assess your current practices, review the latest evidence and best practices shared by leaders in the field, and create your own action plan to ensu... |
|
|
HER3 in NSCLC " Navigating New Frontiers in Targeted Therapy
In patients with non-small cell lung cancer (NSCLC), human epidermal growth factor receptor 3 (HER3) is associated with both advanced disease and resistance to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)"directed therapies. Although there are therapeutic options targeting EGFR (HER1) and HER2, the potential of HER3 as an anti-cancer target has been largely overlooked. Overexpression of HER3 in most patients with NSCLC positions it as an appealing therapeutic targ... |
|
|
Advances in Recurrent/Metastatic Nasopharyngeal Carcinoma: Immunotherapy and Biomarkers
Target Audience
This activity was developed for medical oncologists, head and neck surgeons, radiation oncologists, physician associates, nurse practitioners, nurses and pharmacists involved in the care of patients diagnosed with metastatic nasopharyngeal carcinoma (NPC).
Program Overview
Greater understanding of the tumor microenvironment of nasopharyngeal carcinoma (NPC) has led to the introduction of immunotherapy into the NPC treatment landscape. Incorporating immunotherapy has change... |
|
|
Management of Cancer Pain: Current Guidelines
STATEMENT OF NEED
Patients with cancer often suffer from a range of symptoms that negatively impact their quality of life. Among the most significant of these symptoms is pain, which can be caused by surgery, radiation, chemotherapy, targeted therapy, diagnostic procedures, and/or supportive care measures. Between 20% and 50% of patients with cancer experience pain, including moderate-to-severe pain in approximately 80% of patients with advanced-stage cancer (NCI, 2023). Despite awareness a... |
|
|
Management of Venous Thromboembolism in Ambulatory Patients With Cancer
STATEMENT OF NEED
Venous thromboembolism (VTE) is a common and potentially deadly complication in patients with cancer. The risk of cancer-related VTE has risen in the past 2 decades, with up to 15% of patients with cancer now experiencing VTE. Oncology nurses are ideally situated to assist in the identification of patients at risk for thrombotic events. This activity will discuss strategies for early identification of patients receiving outpatient (ambulatory) chemotherapy who are at high ... |
|
|
Clinical Competence in Breast MR, Volume 2
Clinical Competence in Breast MR, volume 2 meets ACR CME requirements for facility accreditation in Breast MR. Reaccredited in 2023, the program contains 100 comprehensive Breast MR cases. The cases include detailed patient histories, a robust assortment of images, dynamic sequences and teaching points from a nationally renowned faculty. This review explores the many indications for malignant and benign disease, featuring nodules, tumors and patterns of enhancement encountered in every day... |
|